• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Rheum Dis Clinical Characteristics and Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) and Rheumatic Disease: A Comparative Cohort

tetano

Editor, Senior Moderator
Ann Rheum Dis


. 2020 May 26;annrheumdis-2020-217888.
doi: 10.1136/annrheumdis-2020-217888. Online ahead of print.
Clinical Characteristics and Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) and Rheumatic Disease: A Comparative Cohort Study From a US 'Hot Spot'


Kristin M D'Silva[SUP] 1 2 [/SUP], Naomi Serling-Boyd[SUP] 1 [/SUP], Rachel Wallwork[SUP] 1 [/SUP], Tiffany Hsu[SUP] 3 [/SUP], Xiaoqing Fu[SUP] 1 2 [/SUP], Ellen M Gravallese[SUP] 3 [/SUP], Hyon K Choi[SUP] 2 [/SUP], Jeffrey A Sparks[SUP] 3 [/SUP], Zachary S Wallace[SUP] 4 2 [/SUP]



Affiliations

Abstract

Objective: To investigate differences in manifestations and outcomes of coronavirus disease 2019 (COVID-19) infection between those with and without rheumatic disease.
Methods: We conducted a comparative cohort study of patients with rheumatic disease and COVID-19 (confirmed by severe acute respiratory syndrome coronavirus 2 PCR), compared in a 1:2 ratio with matched comparators on age, sex and date of COVID-19 diagnosis, between 1 March and 8 April 2020, at Partners HealthCare System in the greater Boston, Massachusetts area. We examined differences in demographics, clinical features and outcomes of COVID-19 infection. The main outcomes were hospitalisation, intensive care admission, mechanical ventilation and mortality.
Results: We identified 52 rheumatic disease patients with COVID-19 (mean age, 63 years; 69% female) and matched these to 104 non-rheumatic disease comparators. The majority (39, 75%) of patients with rheumatic disease were on immunosuppressive medications. Patients with and without rheumatic disease had similar symptoms and laboratory findings. A similar proportion of patients with and without rheumatic disease were hospitalised (23 (44%) vs 42 (40%)), p=0.50) but those with rheumatic disease required intensive care admission and mechanical ventilation more often (11 (48%) vs 7 (18%), multivariable OR 3.11 (95% CI 1.07 to 9.05)). Mortality was similar between the two groups (3 (6%) vs 4 (4%), p=0.69).
Conclusions: Patients with rheumatic disease and COVID-19 infection were more likely to require mechanical ventilation but had similar clinical features and hospitalisation rates as those without rheumatic disease. These findings have important implications for patients with rheumatic disease but require further validation.

Keywords: autoimmune diseases; epidemiology; health services research; outcome and process assessment, health care.
 
Back
Top Bottom